Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Islatravir - Merck Sharp & Dohme

Next Previous
Drug Profile

Islatravir - Merck Sharp & Dohme

Alternative Names: 4-ethynyl-2-fluoro-2-deoxyadenosine; EFdA; MK-8519; MK-8591; MK-8591-eluting implant

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Gilead Sciences; Merck Sharp & Dohme
  • Class Alkynes; Antiretrovirals; Fluorinated hydrocarbons; Purine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections; HIV-1 infections; HIV-2 infections

Most Recent Events

  • 05 Dec 2025 Merck Sharp & Dohme plans a phase II/III trial for HIV-1 infections (Treatment-Naïve, Combination therapy) in January 2026 (PO) (NCT07266831)
  • 09 Mar 2025 Pharmacokinetics data from a pharmacokinetics trial in HIV-1 infections presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI-2025)
  • 30 Jan 2025 Merck Sharp & Dohme Corp completes a phase II trial for HIV-1 Infection (Combination therapy) in France, Switzerland and USA (NCT04564547) (EudraCT2020-003071-18)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top